{name}
{subtitle}
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~37 mi. (Frankfurt, Germany, +192 more cities)
facility
Agaplesion Markus Krankenhaus
biomarker
ER Positive, +1 more biomarker
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~37 mi. (Frankfurt, Germany, +199 more cities)
facility
Universitaetsklinikum Frankfurt ( Site 0467)
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
city
~37 mi. (Frankfurt, Germany, +150 more cities)
facility
Universitaetsklinikum Frankfurt ( Site 0403)
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +2 more types
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)
city
~37 mi. (Frankfurt, Germany, +127 more cities)
facility
Universitaetsklinikum Frankfurt ( Site 2107)
drug
lenvatinib, +1 more drug
drug type
immunotherapy, +1 more type
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer
city
~37 mi. (Frankfurt, Germany, +151 more cities)
facility
GSK Investigational Site
drug
niraparib, +1 more drug
drug type
immunotherapy, +1 more type
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~44 mi. (Würzburg, Germany, +130 more cities)
facility
Universitaetsklinikum Wuerzburg ( Site 0265)
drug
BCG solution, +1 more drug
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
city
~44 mi. (Würzburg, Germany, +141 more cities)
facility
GSK Investigational Site
drug type
chemotherapy, +1 more type
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
city
~44 mi. (Würzburg, Germany, +74 more cities)
facility
GSK Investigational Site
drug
belantamab mafodotin, +3 more drugs
drug type
chemotherapy, +2 more types